Entera Bio Ltd（ENTX）股票分析ENTXEntera Bio Ltd

Entera Bio Ltd is an Israel-based clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with unmet medical need and where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Entera Bio Ltd appears to be a good buy right now due to its recent oversubscribed private placement raising $275 million, which will fund its Phase 3 trial for EB613, a promising osteoporosis treatment. The current price of $2.92 is well below the analyst price target of $11, suggesting a potential upside of approximately 276%. Additionally, the stock has shown a year-to-date change of +64.97%, indicating strong momentum. However, investors should be cautious of the company's high net loss of $7.31 million reported in Q2 2026, which poses a risk to its financial stability.

1 analysts cover ENTX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 10.00.